First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trial.

ABSTRACT:

Background

Understanding how SARS-CoV-2 breakthrough infections impacts the breadth of immune responses against existing and pre-emergent SARS-CoV-2 strains is needed to develop an evidence-based long-term immunisation strategy.

Methods

We performed a randomised, controlled trial to assess the immunogenicity of homologous (BNT162b2) versus heterologous (mRNA-1273) booster vaccination in 100 BNT162b2-vaccinated infection-naïve individuals enrolled from October 2021. Post hoc analysis was performed to assess the impact of SARS-CoV-2 infection on humoral and cellular immune responses against wild-type SARS-CoV-2 and/or Omicron subvariants.

Findings

93 participants completed the study at day 360. 71% (66/93) of participants reported first SARS-CoV-2 Omicron infection by t

SUBMITTER: Poh XY 

PROVIDER: S-EPMC11367514 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature